Enlivex (ENLV) vs Genprex (GNPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Enlivex is the larger company by market cap ($2.0 million vs $1.9 million), about 1.0 times the size. On valuation, Enlivex trades at a lower trailing P/E (0.0x vs 0.0x for Genprex).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | GNPX |
|---|---|---|
| Share price | $1.05 | $1.45 |
| Market cap | $2.01M | $1.94M |
| 1-day change | -11.76% | -13.17% |
| P/E ratio (TTM) | 0.00 | 0.01 |
| EPS (TTM) | $7,904.00 | $98.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.24B | $-16.23M |
| 52-week high | $434.40 | $80.96 |
| 52-week low | $1.00 | $1.45 |
| Distance from 52-week high | -99.76% | -98.21% |
| Analyst consensus | none | — |
| Avg. price target upside | +7519.05% | — |
| Average volume | 73.14K | 168.88K |
| Shares outstanding | 1.91M | 1.33M |
| Employees | 34 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genprex trades at a higher earnings multiple (0.0x vs 0.0x trailing P/E).
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About Genprex
GNPX stock →Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
ENLV vs GNPX FAQ
Which is bigger, Enlivex or Genprex?
Enlivex (ENLV) is larger, with a market capitalization of $2.01M compared with $1.94M for Genprex (GNPX).
Which has the lower P/E ratio, ENLV or GNPX?
ENLV has the lower trailing P/E at 0.0, versus 0.0 for GNPX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Enlivex and Genprex in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.